Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluatePharma World Preview 2015, Outlook to 2020 

EvaluatePharma World Preview 2015, Outlook to 2020

 EvaluatePharma World Preview 2015 Outlook to 2020

The eighth edition of the EvaluatePharma® World Preview 2015, Outlook to 2020 report brings together many of our analyses to provide a top level insight, from the world's financial market, into the expected performance of the industry between now and 2020.

If there was any doubt that the pharmaceutical industry is entering a period of sustained growth it should be put to rest by this report showing prescription drug sales are set to advance at almost 5% a year until 2020. 

Watch Anthony Raeside, Head of Research at Evaluate, discussing World Preview 2015 at BIO 2015. 

Key highlights in EvaluatePharma® World Preview 2015, Outlook to 2020 include:

  • Worldwide prescription drug sales are expected to reach almost $1 trillion by 2020 (CAGR: 4.8% between 2014 and 2020)
  • Key prescription drug sales jumped 4.9% in 2014, driven by an 8.9% surge in USA sales; Europe returns to growth at 2.4%; Japan slumps 2.6% in yen
  • Industry's R&D pipeline valued at $493bn; Gilead's potential new combination hepatitis C product most valuable
  • Humira remained the top-selling product in 2014 with sales of $13bn; Sovaldi debuts at number two with sales of $10bn
  • A record number of new drugs were approved by the US FDA in 2014; sales potential increases by 45%
  • AbbVie's Humira continues to account for over 25% of the anti-rheumatic market in 2020
  • Gilead continues to dominate the anti-viral segment in 2020 capturing over 50% of the entire market

Report Executive Summary

Press Release

Download EvaluatePharma World Preview 2015